Street Analysts View On Vulcan Materials Company (VMC), Idera Pharmaceuticals, Inc. (IDRA)

Vulcan Materials Company (NYSE:VMC) notched a -4.43% intraday decline moving at $125.2. When the opening bell rang, the price was $130.13. The number of shares that were traded during the day was 2.36 million, which corresponds to its 3-month volume average of 1.26 million shares a day.

Vulcan Materials Company (VMC) Analyst Opinion

Vulcan Materials Company has a consensus outperform rating from 15 Wall Street analysts, and the number of shares currently sold short amount to at least 3.45% of shares outstanding. The stock sank -6.13% last month and is down -2.47 this year. Wall Street is only getting more bullish on the stock, with 12 of analysts who cover VMC having a buy-equivalent rating. Analysts have placed a $144.08 price target on Vulcan Materials Company, suggesting a 15.08% gain from recent close. It’s currently trading about -11.33% below its 52-week high.

Vulcan Materials Company Earnings Surprise

Vulcan Materials Company (VMC) failed to surprise the stock market in its last reported earnings when it earned $1.04 a piece versus the consensus-estimated $1.05. Its revenue totaled $1.07 billion up 4.09% from the previous quarter.

Vulcan Materials Company (NYSE:VMC) Intraday View

This stock (VMC) is ahead of its 52-week low with 14.92%. Its last month’s stock price volatility remained 4.03% which for the week stands at 2.64%. The share price has moved backward from its 20 days moving average, trading at a distance of -7.34% and stays -2.63% away from its 50 days moving average. Over the last five days, shares have faced -9.88% losses and now is up 0.81% since hitting its 200-day moving average of $122.95. Vulcan Materials Company (VMC) has made its way to a 12-month decline of -2.86%.

Turning to Idera Pharmaceuticals, Inc. (NASDAQ:IDRA), its shares were trading at $1.83 a gain of $0.03, on the trading floor. The stock, after opening at $1.8, touched a high of $1.9 before paring much of its gains. So far, analysts are sticking with their bullish recommendations with the consensus call at 1.6. Idera Pharmaceuticals, Inc. has 2 buy ratings, 0 holds and 0 sells even after the stock tumbled -36.24% from its high of $2.87 to a $366.51 million market value through last close.

Idera Pharmaceuticals, Inc. (IDRA) Consensus Price Target

The company’s consensus rating on Reuter’s scale slipped from 1.71 to 1.67 during a month. Analysts set a 12-month price target of $5.4 a share. The target implies a 195.08% spike from where the shares are currently trading. Also, the current price highlights a discount of 337.16% to analysts’ high consensus price target.

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) Intraday Trading

The counter witnessed a trading volume of 2.47 million shares versus an average volume of 2.24 million shares during last trading session. Its last month’s stock price volatility remained 5.33% which for the week approaches 7.13%. The lowest price the stock reached in the last trading day was $1.79 and compares with the $1.32 52-week low. The stock recovered 38.64% since its low point and has performed -13.27% year-to-date.

Previous articleAnalysts Are Gushing Over Amdocs Limited (DOX), Incyte Corporation (INCY)
Next articleAnalyst Commentary On Akamai Technologies, Inc. (AKAM), Cascadian Therapeutics, Inc. (CASC)